Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2005
Reporting Period: Three and nine months ended October 2, 2005
This filing serves as a conduit for a press release (Exhibit 99.1) announcing financial results. The filing explicitly states it is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the input text.
Notable Non-GAAP Measure: The filing highlights that the press release includes net loss per share information that excludes a one-time charge for in-process research and development (IPR&D) related to the acquisition of CyVera Corporation in April 2005.
Material Changes and Unusual Items
- Acquisition Impact: A one-time charge for IPR&D associated with the April 2005 acquisition of CyVera Corporation is identified as a material unusual item.
- Non-GAAP Presentation: Management presents adjusted net loss per share to facilitate period-to-period comparison by excluding the infrequent CyVera acquisition charge.
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, outlook figures, or a detailed list of risks. Management commentary is limited to the rationale for presenting non-GAAP financial measures to better assess core business trends.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the attached press release (Exhibit 99.1).
- Confirm the exact dollar amount of the one-time IPR&D charge related to the CyVera Corporation acquisition.
- Review the reconciliation between GAAP and non-GAAP net loss per share provided in the press release.
- Assess the impact of the CyVera acquisition on the company's long-term R&D pipeline and financial position.